Millions of Americans use credit cards to purchase goods every day. The Durbin Marshall credit card mandates put the secure transactions you rely on at risk, leaving you vulnerable to hackers and foreign cybercriminals that want your data. Hackers win. You lose. Guard your card before it's too late. Tell Congress your data security is not for sale

and oppose the Durbin Marshall credit card mandates. Paid for by Electronic Payments Coalition.

Here's your morning TNB Tech Minute for Monday, November 17th. I'm Zoe Colkin for the Wall Street Journal.

X-Peng significantly narrowed its net loss in the third quarter due to robust sales and margins,

bringing the Chinese carmaker close to profitability. Despite a competitive Chinese auto market,

X-Peng continued its strong sales streak, with deliveries reaching a new

high in October, supported by its advanced autonomous driving technology. Earlier this month,

the company unveiled its humanoid robot iron, with plans for mass production by the end of next

year, as well as plans to release three Robotaxi models in 2026 for ride-hailing services.

Analysts expect it will become profitable in the fourth quarter.

Prociss, Tencent Holdings' largest shareholder, expects its first half earnings to grow,

boosted by increased profitability at the Chinese tech giant and its own e-commerce business.

The Amsterdam listed technology investor said it expects earnings per share from continuing

operations for the six months through the end of September to be up by up to 37 percent

compared with the year earlier period, reflecting growth in revenue and profitability at the group's

e-commerce operations and its investments, mainly 10 cent, as well as the exclusion of currency

translation losses according to the group.

And Johnson & Johnson has agreed to buy Clinical Stage biotech company HaldDA Therapeutics for just over $3 billion in cash

in a deal that bolsters their oncology pipeline. J&J said the deal is slated to close within the next

few months and adds Haldas' proprietary platform to develop oral, targeted therapies for multiple

types of solid tumors, including prostate cancer.

The company also said it expects the HALDA acquisition will reduce its 2026 adjusted per share

...